Inventiva reloads C-suite as it looks to readout

Inventiva S.A. (NASDAQ:IVA; Euronext:IVA) added a trio of executives to its C-suite as the French biotech looks ahead to a Phase III readout in 4Q26 for lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH). 

Axel-Sven Malkomes, formerly CFO of CureVac AG and an investment banker, will succeed Jean Volatier as CFO, with Volatier becoming EVP finance & corporate social responsibility. Former head of legal Susan Coles is returning to become chief legal officer; she was most recently at Vivet Therapeutics S.A.S. And Pamela Herbster, who led HR and business operations at Sage Therapeutics Inc., has been named chief people officer. Nathalie Harroy previously held the post; like Volatier, she has been with the company since its inception and will take on a new role...